X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs DISHMAN PHARMA - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER DISHMAN PHARMA PFIZER/
DISHMAN PHARMA
 
P/E (TTM) x 31.0 25.1 123.5% View Chart
P/BV x 4.9 3.3 147.2% View Chart
Dividend Yield % 0.7 0.7 99.0%  

Financials

 PFIZER   DISHMAN PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-16
DISHMAN PHARMA
Mar-16
PFIZER/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs2,724374 727.6%   
Low Rs1,611129 1,249.8%   
Sales per share (Unadj.) Rs440.9197.8 222.9%  
Earnings per share (Unadj.) Rs48.721.2 229.6%  
Cash flow per share (Unadj.) Rs75.834.7 218.2%  
Dividends per share (Unadj.) Rs15.002.00 750.0%  
Dividend yield (eoy) %0.70.8 87.1%  
Book value per share (Unadj.) Rs462.9179.9 257.3%  
Shares outstanding (eoy) m45.7580.69 56.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.91.3 386.4%   
Avg P/E ratio x44.511.9 375.1%  
P/CF ratio (eoy) x28.67.2 394.7%  
Price / Book Value ratio x4.71.4 334.7%  
Dividend payout %30.89.4 326.6%   
Avg Mkt Cap Rs m99,16320,306 488.4%   
No. of employees `0002.90.8 348.5%   
Total wages/salary Rs m2,7585,355 51.5%   
Avg. sales/employee Rs Th6,981.719,252.7 36.3%   
Avg. wages/employee Rs Th954.56,459.5 14.8%   
Avg. net profit/employee Rs Th771.12,064.1 37.4%   
INCOME DATA
Net Sales Rs m20,17015,961 126.4%  
Other income Rs m857265 323.1%   
Total revenues Rs m21,02816,226 129.6%   
Gross profit Rs m4,3104,103 105.0%  
Depreciation Rs m1,2391,091 113.6%   
Interest Rs m5944 0.6%   
Profit before tax Rs m3,9232,334 168.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m990-   
Tax Rs m1,794624 287.7%   
Profit after tax Rs m2,2281,711 130.2%  
Gross profit margin %21.425.7 83.1%  
Effective tax rate %45.726.7 171.2%   
Net profit margin %11.010.7 103.0%  
BALANCE SHEET DATA
Current assets Rs m16,29911,018 147.9%   
Current liabilities Rs m7,5949,517 79.8%   
Net working cap to sales %43.29.4 458.9%  
Current ratio x2.11.2 185.4%  
Inventory Days Days65110 59.1%  
Debtors Days Days2635 73.9%  
Net fixed assets Rs m8,62216,304 52.9%   
Share capital Rs m458161 283.5%   
"Free" reserves Rs m20,72212,907 160.6%   
Net worth Rs m21,18014,516 145.9%   
Long term debt Rs m254,189 0.6%   
Total assets Rs m29,13729,805 97.8%  
Interest coverage x755.53.5 21,765.6%   
Debt to equity ratio x00.3 0.4%  
Sales to assets ratio x0.70.5 129.3%   
Return on assets %7.78.9 86.0%  
Return on equity %10.511.8 89.2%  
Return on capital %19.017.5 108.3%  
Exports to sales %0.124.8 0.2%   
Imports to sales %17.53.7 467.9%   
Exports (fob) Rs m123,956 0.3%   
Imports (cif) Rs m3,526596 591.3%   
Fx inflow Rs m524,952 1.0%   
Fx outflow Rs m140697 20.1%   
Net fx Rs m-884,255 -2.1%   
CASH FLOW
From Operations Rs m3,4362,786 123.3%  
From Investments Rs m-6,991-1,529 457.3%  
From Financial Activity Rs m-619-941 65.8%  
Net Cashflow Rs m-4,174316 -1,319.1%  

Share Holding

Indian Promoters % 0.0 61.4 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 3.7 202.7%  
FIIs % 4.9 12.7 38.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 22.1 107.2%  
Shareholders   85,207 46,261 184.2%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC LTD  

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of PNB Fraud, Rising Troubles at PSBs, and Top Cues in Focus Today(Pre-Open)

Share markets in India closed on a negative note yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 236 points and the NSE Nifty closed down by 74 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Feb 19, 2018 (Close)

TRACK PFIZER

PFIZER - J.B.CHEMICALS COMPARISON

COMPARE PFIZER WITH

MARKET STATS